New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation

Elizabeth J. Shpall, Salomon M. Stemmer, Scott I. Bearman, Susan Myers, Malcolm Purdy, Roy B. Jones

Research output: Contribution to journalArticlepeer-review

Abstract

High-dose chemotherapy and autologous bone marrow transplantation (ABMT) are commonly used to treat selected patients with high-risk breast cancer. A limitation of ABMT is that clonogenic cancer cells could be collected with the bone marrow and produce a relapse of disease when reinfused into patients. Purging the marrow ex vivo may eliminate the tumor cells, but it can also delay engraftment. We employed two different purging methods whereby breast cancer cells were depleted without delaying engraftment. The addition of WR-2721 (amifostine) to 4-hydroperoxycyclophosphamide (4-HC) reduced the time to engraftment by 10 days compared with marrow purged with 4-HC alone (26 versus 37 days, respectively). The positive selection of CD34+ hematopoietic progenitors produced engraftment within 21 days. The use of granulocyte colony-stimulating factor (G-CSF) accelerated the engraftment time of CD34+ hematopoietic progenitors to 11 days.

Original languageEnglish
Pages (from-to)S19-S23
JournalBreast Cancer Research and Treatment
Volume26
Issue number1
DOIs
StatePublished - Jan 1993
Externally publishedYes

Keywords

  • 4-hydroperoxycyclophoshamide (4-HC)
  • amifostine
  • autologous bone marrow transplantation (ABMT)
  • breast cancer
  • marrow purging

Fingerprint

Dive into the research topics of 'New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation'. Together they form a unique fingerprint.

Cite this